Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation

Technology appraisal guidance
Reference number: TA256
Published: 23 May 2012
Last updated: 02 July 2021

Appendix A: provisional matrix of stakeholders

Appendix A: provisional matrix of stakeholders

Appendix A: provisional matrix of stakeholders
04 February 2013
(106.76 Kb 31 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 30 January 2013